Association of polymorphisms of rs179247 and rs12101255 in thyroid stimulating hormone receptor intron 1 with an increased risk of Graves’ disease: A meta-analysis

Abstract

The polymorphisms of thyroid stimulating hormone receptor (TSHR) intron 1 rs179247 and rs12101255 have been found to be associated with Graves’ disease (GD) in genetic studies. In the present study, we conducted a meta-analysis to examine this association. Two reviewers systematically searched eligible studies in PubMed, Web of Science, Embase and China Biomedical Literature Database (CBM). A meta-analysis on the association between GD and TSHR intron 1 rs179247 or rs12101255 was performed. The odd ratios (OR) were estimated with 95% confidence interval (CI). Meta package in R was used for the analyses. Seven articles (13 studies) published between 2009 and 2014, involving 5754 GD patients and 5768 controls, were analyzed. The polymorphism of rs179247 was found to be associated with an increased GD risk in the allele analysis (A vs. G: OR=1.40, 95% CI=1.33–1.48) and all genetic models (AA vs. GG: OR=1.94, 95% CI=1.73–2.19; AA+AG vs. GG: OR=1.57, 95% CI=1.41–1.74; AA vs. AG+GG: OR=1.54, 95% CI=1.43–1.66). The site rs12101255 also conferred a risk of GD in the allele analysis (T vs. C: OR=1.50, 95% CI=1.40–1.60) and all genetic models (TT vs. CC: OR=2.22, 95% CI=1.92–2.57; TT+TC vs. CC: OR=1.66, 95% CI=1.50–1.83; TT vs. TC+CC: OR=1.74, 95% CI=1.53–1.98). Analysis of the relationship between rs179247 and Graves’ ophthalmopathy (GO) showed no statistically significant correlation (A vs. G: OR=1.02, 95% CI=0.97–1.07). Publication bias was not significant. In conclusion, GD is associated with polymorphisms of TSHR intron 1 rs179247 and rs12101255. There is no association between rs179247 SNPs and GO.

Keywords

Graves’ disease / Graves’ ophthalmopathy / genetic polymorphism / meta-analysis

References

[1] WeetmanAP. Graves’ disease. N Engl J Med, 2000, 343(17): 1236-1248 PMID: 11071676

[2] BartalenaL. Diagnosis and management of Graves disease: a global overview. Nat Rev Endocrinol, 2013, 9(12): 724-734 PMID: 24126481

[3] TengW, ShanZ, TengX, et al. . Effect of iodine intake on thyroid diseases in China. N Engl J Med, 2006, 354(26): 2783-2793 PMID: 16807415

[4] McLeodDS, CooperDS. The incidence and prevalence of thyroid autoimmunity. Endocrine, 2012, 42(2): 252-265 PMID: 22644837

[5] EffraimidisG, WiersingaWM. Mechanisms in endocrinology: autoimmune thyroid disease: old and new players. Eur J Endocrinol, 2014, 170(6): R241-R252 PMID: 24609834

[6] BrixTH, ChristensenK, HolmNV, et al. . A population-based study of Graves’ disease in Danish twins. Clin Endocrinol, 1998, 48(4): 397-400

[7] RoelfsemaF, VeldhuisJD. Thyrotropin secretion patterns in health and disease. Endocr Rev, 2013, 34(5): 619-657 PMID: 23575764

[8] SmithBR, SandersJ, FurmaniakJ. TSH receptor antibodies. Thyroid, 2007, 17(10): 923-938 PMID: 17900238

[9] McLachlanSM, RapoportB. Breaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity. Endocr Rev, 2014, 35(1): 59-105 PMID: 24091783

[10] MuhlbergT, HerrmannK, JobaW, et al. . Lack of association of nonautoimmune hyperfunctioning thyroid disorders and a germline polymorphism of codon 727 of the human thyrotropin receptor in a European Caucasian population. J Clin Endocrinol Metab, 2000, 85(8): 2640-2643 PMID: 10946859

[11] BanY, GreenbergDA, ConcepcionES, et al. . A germline single nucleotide polymorphism at the intracellular domain of the human thyrotropin receptor does not have a major effect on the development of Graves’ disease. Thyroid, 2002, 12(12): 1079-1083 PMID: 12593721

[12] ZeitlinAA, SimmondsMJ, GoughSC. Genetic developments in autoimmune thyroid disease: an evolutionary process. Clin Endocrinol, 2008, 68(5): 671-682

[13] ChistiakovD S K, TurakulovRI, et al. . Further studies of genetic susceptibility to Graves’ disease in a Russian population. Med Sci Monit, 2002, 8(3): CR180-CR184 PMID: 11887032

[14] HoSC, GohSS, KhooDH, et al. . Association of Graves’ disease with intragenic polymorphism of the thyrotropin receptor gene in a cohort of Singapore patients of multi-ethnic origins. Thyroid, 2003, 13(6): 523-528 PMID: 12930595

[15] DechairoBM, ZabanehD, CollinsJ, et al. . Association of the TSHR gene with Graves’ disease: the first disease specific locus. Eur J Hum Genet, 2005, 13(11): 1223-1230 PMID: 16106256

[16] HirataniH, BowdenDW, IkegamiS, et al. . Multiple SNPs in intron 17 of thyrotropin receptor are associated with Graves disease. J Clin Endocrinol Metab, 2005, 90(5): 2898-2903 PMID: 15741259

[17] BrandOJ, BarrettJC, SimmondsMJ, et al. . Association of the thyroid stimulating hormone receptor gene (TSHR) with Graves’ disease. Hum Mol Genet, 2009, 18(9): 1704-1713 PMID: 19244275

[18] LiuL, WuHQ, WangQ, et al. . Association between thyroid stimulating hormone receptor gene intron polymorphisms and autoimmune thyroid disease in a Chinese Han population. Endocr J, 2012, 59(8): 717-723 PMID: 22673349

[19] PloskiR, BrandOJ, Jurecka-LubienieckaB, et al. . Thyroid stimulating hormone receptor (TSHR) intron 1 variants are major risk factors for Graves’ disease in three European Caucasian cohorts. PloS one, 2010, 5(11): e15512 PMID: 21124799 PMCID: 2991361

[20] InoueN, WatanabeM, KatsumataY, et al. . Different genotypes of a functional polymorphism of the TSHR gene are associated with the development and severity of Graves’ and Hashimoto’s diseases. Tissue Antigens, 2013, 82(4): 288-290 PMID: 23962080

[21] WangHL, YangL, JiaZ, et al. . Correlation of gene polymorphism and Graves’ disease in Han nationality in the coastal region of Shandong Province. Chin J Endocrinol Metabol (Chinese), 2013, 29(2): 108-111

[22] WangR, ZhangX, LiuBL, et al. . Association of polymorphisms of TSHR gene intron 1 with Graves disease. Chin J Endocrinol Metabol (Chinese), 2012, 28(4): 306-310

[23] YangSY, LiuW, XueLQ, et al. . Relation between poly-morphisms in TSHR gene intron 1 and Graves’s disease. Chin J Endocrinol Metabol (Chinese), 2011, 27(6): 478-481

[24] LiuBL, YangSY, LiuW, et al. . Refined association of TSH receptor susceptibility locus to Graves’ disease in the Chinese Han population. Eur J Endocrinol, 2014, 170(1): 109-119 PMID: 24144966

[25] ColobranR A, MdelP, FanerR, et al. . Association of an SNP with intrathymic transcription of TSHR and Graves’ disease: a role for defective thymic tolerance. Hum Mol Genet, 2011, 20(17): 3415-3423 PMID: 21642385

[26] XuLD, ZhangXL, SunHM, et al. . Lack of association between thyroid-stimulating hormone receptor haplotypes and Graves’ disease in a northern Chinese population. Tissue Antigens, 2011, 77(1): 2 PMID: 21155717

[27] MenconiF, MarcocciC, MarinoM. Diagnosis and classification of Graves’ disease. Autoimmun Rev, 2014, 13(4-5): 398-402 PMID: 24424182

[28] EcksteinAK, JohnsonKT, ThanosM, et al. . Current insights into the pathogenesis of Graves’ orbitopathy. Horm Metab Res, 2009, 41(6): 456-464 PMID: 19530272

[29] Jurecka-LubienieckaB, PloskiR, KulaD, et al. . Association between polymorphisms in the TSHR gene and Graves’ orbitopathy. PloS One, 2014, 9(7): e102653 PMID: 25061884 PMCID: 4111286

[30] XiongJQ, LiY, HuangK, et al. . Association between DAPK1 promoter methylation and cervical cancer: a meta-analysis. PloS One, 2014, 9(9): e107272 PMID: 25268905 PMCID: 4182030

[31] ChuX, PanCM, ZhaoSX, et al. . A genome-wide association study identifies two new risk loci for Graves’ disease. Nat Genet, 2011, 43(9): 897-901 PMID: 21841780

[32] BufaloN D, SantosRB, MarcelloMA, et al. . TSHR intronic polymorphisms (rs179247 and rs12885526) and their role in the susceptibility of the Brazilian population to Graves’ disease and Graves’ ophthalmopathy. J Endocrinol Invest, 2014

[33] ChistiakovDA. Thyroid-stimulating hormone receptor and its role in Graves’ disease. Mol Genet Metab, 2003, 80(4): 377-388 PMID: 14654350

[34] GerdingMN, TerweeCB, DekkerFW, et al. . Quality of life in patients with Graves’ ophthalmopathy is markedly decreased: measurement by the medical outcomes study instrument. Thyroid, 1997, 7(6): 885-889 PMID: 9459632

[35] GianoukakisAG, SmithTJ. Recent insights into the pathogenesis and management of thyroid-associated ophthalmopathy. Curr Opin Endocrinol Diabetes Obes, 2008, 15(5): 446-452 PMID: 18769218 PMCID: 3712753

[36] LiH, ChenQ. Genetic susceptibility to Grave’s disese. Front Biosci, 2013, 18: 1080-1087

[37] BednarczukT, GopinathB, PloskiR, et al. . Susceptibility genes in Graves’ ophthalmopathy: searching for a needle in a haystack?. Clin Endocrinol, 2007, 67(1): 3-19

[38] GuLQ, ZhuW, ZhaoSX, et al. . Clinical associations of the genetic variants of CTLA-4, Tg, TSHR, PTPN22, PTPN12 and FCRL3 in patients with Graves’ disease. Clin Endocrinol, 2010, 72(2): 248-255

[39] YinX, LatifR, BahnR, et al. . Influence of the TSH receptor gene on susceptibility to Graves’ disease and Graves’ ophthalmopathy. Thyroid, 2008, 18(11): 1201-1206 PMID: 18925838 PMCID: 2857451